Overview

Ruxolitinib for Cancer Cachexia

Status:
Not yet recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

To assess toxicity with use of ruxolitinib in NSCLC cachexia patients; to associate levels of JAK/STAT signaling in blood, adipose, and muscle pre- and post-ruxolitinib treatment with changes in cachexia and anorexia.

Phase:

Phase 1

Details

Lead Sponsor:

Puneeth Iyengar

Collaborator:

Incyte Corporation